BMC Women's Health (Oct 2004)

Screening for known mutations in <it>EIF2B </it>genes in a large panel of patients with premature ovarian failure

  • Bakalov Vladimir K,
  • Vanderhoof Vien H,
  • Schiffmann Raphael,
  • Gauthier-Barichard Fernande,
  • Fogli Anne,
  • Nelson Lawrence M,
  • Boespflug-Tanguy Odile

DOI
https://doi.org/10.1186/1472-6874-4-8
Journal volume & issue
Vol. 4, no. 1
p. 8

Abstract

Read online

Abstract Background Premature Ovarian Failure (POF), defined as the development of hypergonadotropic amenorrhea before the age of 40 years, occurs in about 1% of all women. Other than karyotype abnormalities, very few genes are known to be associated with this ovarian dysfunction. Recently, in seven patients who presented with POF and white matter abnormalities on MRI (ovarioleukodystrophy) eight mutationswere found in EIF2B2, 4 and 5. Methods To further test the involvement of known mutations of EIF2B genes in POF, we screened 93 patients with POF who did not have identified leukodystrophy or neurological symptoms. We evaluated these eight mutations and two additional mutations that had been found in patients with milder forms of eIF2B-related disorders. We used restriction enzymes and direct sequencing. Results None of the known mutations in EIF2B genes, either homozygous or heterozygous, were identified in our 93 patients with pure 46,XX POF. The upper 95 % confidence limit of the proportion 0/93 is 3.2%. Conclusions We conclude that eIF2B mutations, already described in cases of POF associated with white matter abnormalities, are an uncommon cause of pure spontaneous premature ovarian failure.